CAUGHT ON CAMERA- W.H.O Scientists Question Safety Of Vaccines (9 min video)
Doctors Are Starting To Question The Narrative As Well
https://www.brighteon.com/3dec332d-fd96-4654-a72f-55b702bd9262
First part of TEXT of video
We Don’t Have The Amount Of Safety Science Or Monitoring Systems We Need
“There’s a lot of safety science that’s needed.” – Prof. Heidi Larson, Ph.D.
“We can’t over emphasize the fact that “we really don’t have very good safety monitoring systems in many countries. “…”we are not able to give clear-cut answers when people ask questions about the deaths that have occurred due to a particular vaccine. “One should be able to give a very factual account of what exactly has happened and what the cause of deaths are, but in most cases”there is some obfuscation at that level and therefore there is less and less trust.”- Dr. Soumya Swaminathan
Adjuvants Are Necessary and Unsafe
“Every time that there is an association… the first accusation is that it is the adjuvant, and yet without adjuvants, we are not going to have the next generation of vaccines… so the challenge that we have in front of us is how to build confidence. … when we add adjuvants it is essential. We do not add adjuvants to vaccines because we want to do so…” – Dr. Martin Howell Friede – WHO/HO/IVR
“It seems to me that adjuvants mulitply the immunogenicity of the antigens that they are added to, and that is their intention. It seems to me they mulitply the reactogenicity in many instances, and therefore, it seems to me that it is not unexpected if they [adjuvants] mulitply the incidence of adverse reactions.” – Dr. Stephen Evans – Professor of Pharmacoepidemiology
“Those of us in this room who are beyond the age of 50 who have had the pleasure of having the recent shingles vaccine will know that this does have quite significant local reactogenicity. If you got the vaccine, you know you got the vaccine. But this is not the major health concern. The major health concern we are seeing are accusations of long-term effects.” – Dr. Martin Howell Friede – WHO/HO/IVR
Clinical Trials Suffer From Having Small Numbers Of Participants, And Participants From Limited Demographics
“So, in our clinical trials, we are actually using relatively small sample sizes and when we do that, we’re at risk of tyrany of small numbers. Which is, you just need a single case of Wegener’s Granulomatosis, and your vaccine has to solve… [a null hypothesis.] [We need] better biomarkers, better mechanistic understanding of how these things work, so we can better understand adverse events as they come up.” – Dr. David Kaslow, MD
“One of the additional issues that complicates safety evaluation is that if you look at, and you struggle with, the length of follow-up that should be adequate in, let’s say a pre-licensure or even a post-marketing study…. As you mentioned, pre-licensure trials may not be powered enough. It’s also the subject population that you administer the adjuvant to. Because we’ve seen data presented to us where a particular adjuvant did nothing when administered to a particular population, and its usually the elderly, compared to administering the same formulation to younger aged strata. So these are the things which need to be considered as well and further complicate the safety of adjuvants combined with vaccine antigens.” – Dr. Marion Gruber, Ph.D. – FDA
Scroll down for remainder of text at
https://www.kerririvera.com/behind-the-scenes-with-vaccines-the-w-h-o-discusses-risks-and-public-perception-of-vaccinations/